Related Experiment Video
Updated: Jun 12, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Late onset purple toe syndrome with warfarin successfully treated with fondaparinux
Joseph P Rindone1, Chadwick K Mellen, James D Eliason
1Department of Clinical Pharmacy, Northern Arizona VA Health Care System, Prescott, 86313, USA. joseph.rindone@med.va.gov
Abstract:
Purple toe syndrome is a rarely reported adverse effect of warfarin. In all described cases, the syndrome occurred relatively quickly after initiation of warfarin with little recommendation for treatment in patients needing continued anticoagulation. We encountered a patient who developed purple toes after 1 year of warfarin therapy. The warfarin was stopped, and fondaparinux was substituted with prompt resolution of all his symptoms. This is the first case describing late onset purple toe syndrome with warfarin with successful substitution with fondaparinux.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
